PACTR201205000383208Other2 期
A multiple arm, multiple stage (MAMS), phase 2, open label, randomized, controlled clinical trial to evaluate four treatment regimens including SQ109, two increased doses of rifampicin, and moxifloxacin in adult subjects with newly diagnosed, smear¿positive pulmonary tuberculosis
Prof. Karl Walter Jauch, Medical Director, Klinikum of the Universtiy of Munich0 个研究点目标入组 372 人开始时间: 2012年5月24日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- Other
- 发起方
- 入组人数
- 372
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Year(s) 至 150 Year(s)（—）
- 性别
- All
入选标准
- •1. The patient has given free, signed written or witnessed oral informed consent for study participation prior to all trial-related procedures, including HIV testing. ago.
- •2. The patient has a diagnosis of pulmonary TB.
- •3. An adequate sputum bacterial load is confirmed by a Ziehl-Neelsen stained smear in the study laboratory.
- •4. The patient has a valid rapid test result (GeneXpert MTB/RIF®) from the sputum positive for MTB complex, and indicating susceptibility to Rifampicin.
- •5. The patient is aged at least 18 years at the day of informed consent.
- •6. The patient has a body weight of at least 35 kg, but not more than 90 kg.
- •7. Female patients of childbearing potential must have a negative serum pregnancy test, and consent to practise an effective method of birth control until week 26.
- •8. Male patients must consent to use an effective contraceptive method, if their sexual partner(s) is/are of childbearing potential, and if they are not surgically sterile.
- •9. The patient has a firm home address that is readily accessible for visiting and willingness to inform the study team of any change of address during the treatment and follow-up period, or will be compliant to study schedule and follow-up in the discretion of the investigator.
排除标准
- •1. Circumstances that raise doubt about free, uncoerced consent to study participation.
- •2. Poor General Condition.
- •3. The patient is pregnant or breast-feeding.
- •4. The patient has an HIV infection.
- •5. The patient has a known intolerance to any of the study drugs, or concomitant disorders or conditions for which SQ109, rifampicin, moxifloxacin, or standard TB treatment are contraindicated.
- •6. The patient has an history or evidence of clinically relevant metabolic, gastrointestinal, neurological, psychiatric or endocrine diseases, malignancy, or any other condition that will influence treatment response, study adherence or survival in the judgement of the investigator.
- •7. History of previous TB within the last five years.
- •8. Laboratory: at screening one or more of the following abnormalities were observed for the patient in screening laboratory: AST and/or ALT activity >3x the upper limit of normal, serum total bilirubin level >2.5 times the upper limit of normal, Creatinine clearance (CrCl) level greater than 30 mls/min, Complete blood count with hemoglobin level <7.0 g/dL, Platelet count <50,000/mm3, Serum potassium below the lower level of normal
- •9. ECG findings in the screening ECG: QTcB and/or QTcF of >0.450 s, AV block with PR interval > 0.20 s, prolongation of the QRS complex over 120 milliseconds, other changes in the ECG that are clinically relevant as per discretion of the investigator.
- •10. The patient has had treatment with any other investigational drug within 1 month prior to enrolment.
- •11. Previous anti-TB treatment.
- •12. QT prolonging medications.
- •13. CYP 450 inducers/inhibitors: administration within 30 days prior to dosing.
研究者
相似试验
进行中（未招募）
1 期
A clinical trial of prostate cance aobut therapeutic immunotherapy strategiesmetastatic hormone-sensitive prostate cancerMedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004377-13-ESSOGUG (Spanish Genitourinary Oncologic Group)120
进行中（未招募）
1 期
A clinical trial investigating the use of BTT1023 in patients with PSCPrimary Sclerosing Cholangitis (PSC)MedDRA version: 20.1Level: LLTClassification code 10036732Term: Primary sclerosing cholangitisSystem Organ Class: 100000004871EUCTR2014-002393-37-GBniversity of Birmingham23
已完成
2 期
ITEM - a phase II study of imatinib in the treatment of patients with metastatic uveal melanomaMetastatic eye melanomaEye melanomaCancerISRCTN91548930Clatterbridge Centre for Oncology NHS Foundation Trust (UK)25
已完成
2 期
A prospective, multi-centre, single arm, phase 2 assessment of the efficacy and safety of the combination of ixazomib, thalidomide and dexamethasone (ITD) for relapsed and/or refractory multiple myeloma after 1 to 3 prior lines of therapy.Cancer - MyelomaMultiple MyelomaACTRN12616000894493Professor Andrew Spencer40
进行中（未招募）
2 期
Selected mesenchymal stromal cells to reduce liver inflammatioPrimary sclerosing cholangitis (PSC), autoimmune hepatitis (AIH)Digestive SystemOral and Gastrointestinal/ Diseases of liverISRCTN73586959niversity of Birmingham18